ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files

In today's ACT Brief, we examine why time savings dominates the financial case for RBQM investment, how the FDA is strengthening inspection access and data integrity review, and how data governance models shape real-world evidence quality.